You are here: Industry Insights > Lexicon

News List

Lexicon Completes Safety Review of Telotristat Ethyl in Biliary Tract Cancer americanpharmaceuticalreview
December 30, 2019
Lexicon Pharmaceuticals announced the completion of a safety review of the initial run-in cohort of the Telotristat Ethyl for Advanced Biliary Tract Cancer ...
FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes expressbpd
March 26, 2019
The setback comes as Sanofi works to revive declining sales from its diabetes division and faces increasing pressure from politicians and patient advocacy groups over the rising cost of its insulin products.
Lexicon pain drug advances after clearing early clinical test fiercebiotech
December 25, 2018
A phase 1a trial of Lexicon Pharmaceuticals’ LX9211 has met its primary objectives. The study found the AAK1 inhibitor was well tolerated, teeing Lexicon up to advance the neuropathic pain prospect.....
Lexicon Initiates Patient Dosing in LX9211 Phase 1 Study americanpharmaceuticacreview
September 28, 2017
Lexicon Pharmaceuticals has initiated dosing in a Phase 1 study of LX9211, an orally-administered small molecule for the treatment of neuropathic pain.
Lexicon builds case for Sanofi-partnered diabetes pill fiercebiotech
August 16, 2017
Sanofi is set to file for approval of sotagliflozin in Type 1 diabetes next year.
Lexicon Reports Additional Positive Data from Sotagliflozin Pivotal Phase 3 Study pharmaceutical-technology
August 16, 2017
Lexicon Pharmaceuticals announced additional positive data from the pivotal Phase 3 inTandem2 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor.
Lexicon Reports Additional Positive Data from Pivotal InTandem1 Phase 3 Study for Sotagliflozin americanpharmaceuticalreview
May 12, 2017
Lexicon Pharmaceuticals announced additional positive data from the Phase 3 inTandem1 study.
Catalent Manufactures Lexicon’s XERMELO Following Approval contractpharma
May 10, 2017
To provide commercial supply of first-in-class oral therapy from its Kansas City facility